Vedolizumab Trough level
| Category | Immunology |
|---|---|
| Test background |
Vedolizumab (Entyvio©) is a humanised IgG1 antibody which inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut. Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin |
| Clinical Indications |
For the monitoring of drug trough levels in IBD patients treated with Vedolizumab |
| Reference range | Results are reported between 0.8 µg/ml and 144 µg/ml. In the induction phase of the Entyvio© clinical trials week 6 trough levels were higher in responders than non-responders and higher trough levels were associated with increased mucosal healing in UC patients. |
| Sample & container required | Serum (rust top) vacutainer |
| Sample volume | 0.5ml |
| Sample collection | Samples should be taken just before the next infusion of drug (trough) |
| Transport storage | Transportation at room temperature/ first class post is adequate. Storage at 4 degrees or -20 for long term. |
| Turnaround time | 4 weeks |